The tumor microenvironment of colorectal cancer: Stromal TLR-4 expression as a potential prognostic marker

Journal of Translational Medicine

Volumn 8, Issue , 2010, Pages

  Cammarota, Rosaria ^a   Bertolini, Valentina ^a   Pennesi, Giuseppina ^a   Bucci, Eraldo O ^a   Gottardi, Ornella ^a   Garlanda, Cecilia ^b   Laghi, Luigi ^b   Barberis, Massimo C ^c   Sessa, Fausto ^a,d   Noonan, Douglas M ^d   Albini, Adriana ^a  

^a IRCCS MULTIMEDICA   (Italy)

^b HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^c EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^d UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AZOXYMETHANE; CD15 ANTIGEN; CD31 ANTIGEN; CD68 ANTIGEN; DEXTRAN SULFATE; INTERLEUKIN 6; SCATTER FACTOR; TOLL LIKE RECEPTOR 4; CYTOKINE; LEUKOCYTE ANTIGEN; TLR4 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER RISK; COLON ADENOCARCINOMA; COLON ADENOMA; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOWN REGULATION; GENETIC MARKER; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INNATE IMMUNITY; MOUSE; NONHUMAN; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; STROMA CELL; TISSUE SPECIFICITY; TUMOR MICROENVIRONMENT; ULCERATIVE COLITIS; ANIMAL; COLORECTAL TUMOR; DISEASE MODEL; IMMUNOLOGY; METABOLISM; MOUSE MUTANT; PATHOLOGY;

ANIMALS; ANTIGENS, CD; COLORECTAL NEOPLASMS; CYTOKINES; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, KNOCKOUT; PROGNOSIS; TOLL-LIKE RECEPTOR 4;

EID: 78049484534     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-8-112     Document Type: Article

References (61)

1. Troisi RJ, Freedman AN, Devesa SS. Incidence of colorectal carcinoma in the U.S.: an update of trends by gender, race, age, subsite, and stage, 1975-1994. Cancer 1999, 85:1670-1676. 10.1002/(SICI)1097-0142(19990415)85:8<1670::AID-CNCR5>3.0.CO;2-M, 10223559.
2. Brenner H, Hoffmeister M, Haug U. Should colorectal cancer screening start at the same age in European countries? Contributions from descriptive epidemiology. Br J Cancer 2008, 99:532-535. 10.1038/sj.bjc.6604488, 2527806, 18628760.
3. Bresalier RS. Early detection of and screening for colorectal neoplasia. Gut Liver 2009, 3:69-80. 10.5009/gnl.2009.3.2.69, 2852697, 20431727.
4. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996, 87:159-170. 10.1016/S0092-8674(00)81333-1, 8861899.
5. Witz IP. Tumor-microenvironment interactions: dangerous liaisons. Adv Cancer Res 2008, 100:203-229. full_text, 18620097.
6. Finn OJ. Cancer immunology. N Engl J Med 2008, 358:2704-2715. 10.1056/NEJMra072739, 18565863.
7. Garber K. First results for agents targeting cancer-related inflammation. J Natl Cancer Inst 2009, 101:1110-1112. 10.1093/jnci/djp266, 19671776.
8. Sica A, Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest 2007, 117:1155-1166. 10.1172/JCI31422, 1857267, 17476345.
9. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009, 30:1073-1081. 10.1093/carcin/bgp127, 19468060.
10. DeNardo DG, Coussens LM. Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res 2007, 9:212. 10.1186/bcr1746, 2206719, 17705880.
11. Junankar SR, Eichten A, Kramer A, de Visser KE, Coussens LM. Analysis of immune cell infiltrates during squamous carcinoma development. J Investig Dermatol Symp Proc 2006, 11:36-43. 10.1038/sj.jidsymp.5650024, 17069009.
12. de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006, 6:24-37. 10.1038/nrc1782, 16397525.
13. Mantovani A, Marchesi F, Portal C, Allavena P, Sica A. Linking inflammation reactions to cancer: novel targets for therapeutic strategies. Adv Exp Med Biol 2008, 610:112-127. full_text, 18593019.
14. Zipin-Roitman A, Meshel T, Sagi-Assif O, Shalmon B, Avivi C, Pfeffer RM, Witz IP, Ben-Baruch A. CXCL10 promotes invasion-related properties in human colorectal carcinoma cells. Cancer Res 2007, 67:3396-3405. 10.1158/0008-5472.CAN-06-3087, 17409450.
15. Rosen LS. VEGF-targeted therapy: therapeutic potential and recent advances. Oncologist 2005, 10:382-391. 10.1634/theoncologist.10-6-382, 15967832.
16. Albini A, Sporn MB. The tumour microenvironment as a target for chemoprevention. Nat Rev Cancer 2007, 7:139-147. 10.1038/nrc2067, 17218951.
17. Albini A, Tosetti F, Benelli R, Noonan DM. Tumor inflammatory angiogenesis and its chemoprevention. Cancer Res 2005, 65:10637-10641. 10.1158/0008-5472.CAN-05-3473, 16322203.
18. Arteta B, Lasuen N, Lopategi A, Sveinbjornsson B, Smedsrod B, Vidal-Vanaclocha F. Colon carcinoma cell interaction with liver sinusoidal endothelium inhibits organ-specific antitumor immunity through interleukin-1-induced mannose receptor in mice. Hepatology 51:2172-2182. 10.1002/hep.23590, 20513002.
19. Noonan DM, De Lerma BA, Vannini N, Mortara L, Albini A. Inflammation, inflammatory cells and angiogenesis: decisions and indecisions. Cancer Metastasis Rev 2008, 27:31-40. 10.1007/s10555-007-9108-5, 18087678.
20. Arber N, Levin B. Chemoprevention of colorectal neoplasia: the potential for personalized medicine. Gastroenterology 2008, 134:1224-1237. 10.1053/j.gastro.2008.02.012, 18395100.
21. Bertagnolli MM. Chemoprevention of colorectal cancer with cyclooxygenase-2 inhibitors: two steps forward, one step back. Lancet Oncol 2007, 8:439-443. 10.1016/S1470-2045(07)70139-0, 17466901.
22. Wang D, Dubois RN. The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene 29:781-788. 10.1038/onc.2009.421, 19946329.
23. Harris RE, Beebe-Donk J, Alshafie GA. Similar reductions in the risk of human colon cancer by selective and nonselective cyclooxygenase-2 (COX-2) inhibitors. BMC Cancer 2008, 8:237. 10.1186/1471-2407-8-237, 2529335, 18702823.
24. Baeten CI, Castermans K, Hillen HF, Griffioen AW. Proliferating endothelial cells and leukocyte infiltration as prognostic markers in colorectal cancer. Clin Gastroenterol Hepatol 2006, 4:1351-1357. 10.1016/j.cgh.2006.08.005, 17059898.
25. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313:1960-1964. 10.1126/science.1129139, 17008531.
26. Novick D, Shulman LM, Chen L, Revel M. Enhancement of interleukin 6 cytostatic effect on human breast carcinoma cells by soluble IL-6 receptor from urine and reversion by monoclonal antibody. Cytokine 1992, 4:6-11. 10.1016/1043-4666(92)90029-Q, 1617157.
27. Blay J, Brown KD. Epidermal growth factor promotes the chemotactic migration of cultured rat intestinal epithelial cells. J Cell Physyol 1985, 124:107-112.
28. Plante M, Rubin SC, Wong GY, Federici MG, Finstad CL, Gastl GA. Interleukin-6 level in serum and ascites as a prognostic factor in patients with epithelial ovarian cancer. Cancer 1994, 73:1882-1888. 10.1002/1097-0142(19940401)73:7<1882::AID-CNCR2820730718>3.0.CO;2-R, 8137215.
29. Vener C, Guffanti A, Pomati M, Colombi M, Alietti A, La Targia ML, Bamonti-Catena F, Baldini L. Soluble cytokine levels correlate with the activity and clinical stage of Hodgkin's disease at diagnosis. Leuk Lymphoma 2000, 37:333-339.
30. Chung YC, Chaen YL, Hsu CP. Clinical significance of tissue expression of interleukin-6 in colorectal carcinoma. Anticancer Res 2006, 26:3905-3911.
31. Dougan M, Dranoff G. Inciting inflammation: the RAGE about tumor promotion. J Exp Med 2008, 205:267-270. 10.1084/jem.20080136, 2271001, 18268042.
32. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009, 9:798-809. 10.1038/nrc2734, 19851315.
33. Karin M. The IkappaB kinase - a bridge between inflammation and cancer. Cell Res 2008, 18:334-342. 10.1038/cr.2008.30, 18301380.
34. Poutahidis T, Haigis KM, Rao VP, Nambiar PR, Taylor CL, Ge Z, Watanabe K, Davidson A, Horwitz BH, Fox JG, Erdman SE. Rapid reversal of interleukin-6-dependent epithelial invasion in a mouse model of microbially induced colon carcinoma. Carcinogenesis 2007, 28:2614-2623. 10.1093/carcin/bgm180, 17724375.
35. Rose-John S, Mitsuyama K, Matsumoto S, Thaiss WM, Scheller J. Interleukin-6 trans-signaling and colonic cancer associated with inflammatory bowel disease. Curr Pharm Des 2009, 15:2095-2103. 10.2174/138161209788489140, 19519447.
36. Killeen SD, Wang JH, Andrews EJ, Redmond HP. Bacterial endotoxin enhances colorectal cancer cell adhesion and invasion through TLR-4 and NF-kappaB-dependent activation of the urokinase plasminogen activator system. Br J Cancer 2009, 100:1589-1602. 10.1038/sj.bjc.6604942, 2696751, 19436306.
37. Aderem A, Ulevitch RJ. Toll-like receptors in the induction of the innate immune response. Nature 2000, 406:782-787. 10.1038/35021228, 10963608.
38. Faure E, Thomas L, Xu H, Medvedev A, Equils O, Arditi M. Bacterial lipopolysaccharide and IFN-gamma induce Toll-like receptor 2 and Toll-like receptor 4 expression in human endothelial cells: role of NF-kappa B activation. J Immunol 2001, 166:2018-2024.
39. Vamadevan AS, Fukata M, Arnold ET, Thomas LS, Hsu D, Abreu MT. Regulation of Toll-like receptor 4-associated MD-2 in intestinal epithelial cells: a comprehensive analysis. Innate Immun 2009, 2846239, 19710105.
40. Gribar SC, Anand RJ, Sodhi CP, Hackam DJ. The role of epithelial Toll-like receptor signaling in the pathogenesis of intestinal inflammation. J Leukoc Biol 2008, 83:493-498. 10.1189/jlb.0607358, 18160540.
41. Fukata M, Chen A, Vamadevan AS, Cohen J, Breglio K, Krishnareddy S, Hsu D, Xu R, Harpaz N, Dannenberg AJ, et al. Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology 2007, 133:1869-1881. 10.1053/j.gastro.2007.09.008, 2180834, 18054559.
42. Grau MV, Sandler RS, McKeown-Eyssen G, Bresalier RS, Haile RW, Barry EL, Ahnen DJ, Gui J, Summers RW, Baron JA. Nonsteroidal anti-inflammatory drug use after 3 years of aspirin use and colorectal adenoma risk: observational follow-up of a randomized study. J Natl Cancer Inst 2009, 101:267-276. 10.1093/jnci/djn484, 2644329, 19211442.
43. Carothers AM, Davids JS, Damas BC, Bertagnolli MM. Persistent cyclooxygenase-2 inhibition downregulates NF-{kappa}B, resulting in chronic intestinal inflammation in the min/+ mouse model of colon tumorigenesis. Cancer Res 70:4433-4442. 10.1158/0008-5472.CAN-09-4289, 20484034.
44. Bernasconi P, Barberis M, Baggi F, Passerini L, Cannone M, Arnoldi E, Novellino L, Cornelio F, Mantegazza R. Increased toll-like receptor 4 expression in thymus of myasthenic patients with thymitis and thymic involution. Am J Pathol 2005, 167:129-139. 1603452, 15972959.
45. Garlanda C, Riva F, Veliz T, Polentarutti N, Pasqualini F, Radaelli E, Sironi M, Nebuloni M, Zorini EO, Scanziani E, Mantovani A. Increased susceptibility to colitis-associated cancer of mice lacking TIR8, an inhibitory member of the interleukin-1 receptor family. Cancer Res 2007, 67:6017-6021. 10.1158/0008-5472.CAN-07-0560, 17616656.
46. Kim SJ, Kim JS, Papadopoulos J, Wook Kim S, Maya M, Zhang F, He J, Fan D, Langley R, Fidler IJ. Circulating monocytes expressing CD31: implications for acute and chronic angiogenesis. Am J Pathol 2009, 174:1972-1980. 10.2353/ajpath.2009.080819, 2671284, 19349357.
47. Ramprasad MP, Terpstra V, Kondratenko N, Quehenberger O, Steinberg D. Cell surface expression of mouse macrosialin and human CD68 and their role as macrophage receptors for oxidized low density lipoprotein. Proc Natl Acad Sci USA 1996, 93:14833-14838. 10.1073/pnas.93.25.14833, 26222, 8962141.
48. Brooks SA, Leathem AJ. Expression of the CD15 antigen (Lewis x) in breast cancer. Histochem J 1995, 27:689-693.
49. Garlanda C, Riva F, Polentarutti N, Buracchi C, Sironi M, De Bortoli M, Muzio M, Bergottini R, Scanziani E, Vecchi A, et al. Intestinal inflammation in mice deficient in Tir8, an inhibitory member of the IL-1 receptor family. Proc Natl Acad Sci USA 2004, 101:3522-3526. 10.1073/pnas.0308680101, 373495, 14993616.
50. Doan HQ, Bowen KA, Jackson LA, Evers BM. Toll-like receptor 4 activation increases Akt phosphorylation in colon cancer cells. Anticancer Res 2009, 29:2473-2478. 2901163, 19596916.
51. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2001, 2:675-680. 10.1038/90609, 11477402.
52. Hussain SP, Amstad P, Raja K, Ambs S, Nagashima M, Bennett WP, Shields PG, Ham AJ, Swenberg JA, Marrogi AJ, Harris CC. Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone chronic inflammatory disease. Cancer Res 2000, 60:3333-3337.
53. Walther A, Johnstone E, Swanton C, Midgley R, Tomlinson I, Kerr D. Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer 2009, 9:489-499. 10.1038/nrc2645, 19536109.
54. Kraus S, Arber N. Inflammation and colorectal cancer. Curr Opin Pharmacol 2009, 9:405-410. 10.1016/j.coph.2009.06.006, 19589728.
55. Edwards RA, Witherspoon M, Wang K, Afrasiabi K, Pham T, Birnbaumer L, Lipkin SM. Epigenetic repression of DNA mismatch repair by inflammation and hypoxia in inflammatory bowel disease-associated colorectal cancer. Cancer Res 2009, 69:6423-6429. 10.1158/0008-5472.CAN-09-1285, 2748849, 19638594.
56. Laghi L, Bianchi P, Miranda E, Balladore E, Pacetti V, Grizzi F, Allavena P, Torri V, Repici A, Santoro A, et al. CD3+ cells at the invasive margin of deeply invading (pT3-T4) colorectal cancer and risk of post-surgical metastasis: a longitudinal study. Lancet Oncol 2009, 10:877-884. 10.1016/S1470-2045(09)70186-X, 19656725.
57. Gong R. Multi-target anti-inflammatory action of hepatocyte growth factor. Curr Opin Investig Drugs 2008, 9:1163-1170.
58. Arthur LG, Schwartz MZ, Kuenzler KA, Birbe R. Hepatocyte growth factor treatment ameliorates diarrhea and bowel inflammation in a rat model of inflammatory bowel disease. J Pediatr Surg 2004, 39:139-143. discussion 139-143, 10.1016/j.jpedsurg.2003.10.001, 14966727.
59. Pfannenstiel LW, Lam SS, Emens LA, Jaffee EM, Armstrong TD. Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice. Cell Immunol 263:79-87. 10.1016/j.cellimm.2010.03.001, 20346445.
60. Iwasaki A, Medzhitov R. Regulation of adaptive immunity by the innate immune system. Science 2010, 327:291-295. 10.1126/science.1183021, 20075244.
61. Wang EL, Qian ZR, Nakasono M, Tanahashi T, Yoshimoto K, Bando Y, Kudo E, Shimada M, Sano T. High expression of Toll-like receptor 4/myeloid differentiation factor 88 signals correlates with poor prognosis in colorectal cancer. Br J Cancer 102:908-915. 10.1038/sj.bjc.6605558, 20145615.